Centre for Haemato-Oncology

Welcome to the Centre for Haemato-Oncology, where our main mission is to find cures for haematologic malignancies. We are a centre of excellence in state-of-the-art research and clinical translation, which brings together internationally-recognised basic scientists with top clinical  academics. Our central aim is to understand the biology of leukaemias and lymphomas and harness this knowledge to identify new treatment strategies. Working closely together with the Haemato-oncology department at the St Bartholomew’s Hospital Cancer Centre we are uniquely well placed to implement our findings in clinical practice. Moreover, our Centre is embedded in Barts and The London School of Medicine and Dentistry, one of the UK’s top medical schools, thus offering excellent opportunities for multidisciplinary collaborations.

Our main research themes and their associated faculty include:

  1. Stem cell biology and normal haematopoiesis (Laboratories: Ficz, Ganuza, Kranc, Rouault-Pierre)
  2. Biology and therapeutic targeting of leukaemia (Laboratories: Gribben, Gallipoli, Kranc, Krysov, Riches, Rouault-Pierre, Wrench, Cutillas)
  3. Pathogenesis and treatment of lymphomas (Laboratories: Braun, Okosun, Riches, Fitzgibbon)
  4. Improving immunotherapy in blood malignancies (Laboratories: Davies, Gribben, Le Dieu)

Contact us

Centre Lead: Professor John Gribben

Deputy Centre Lead: Professor Kamil Kranc

Lab Manager: Dr Rebecca Gresham

Centre Administrator: Sara Muradi

3rd Floor, John Vane Science Centre,
Charterhouse Square,
London EC1M 6BQ

Recent Publications

  • Targeting the RNA m6A Reader YTHDF2 Selectively Compromises Cancer Stem Cells in Acute Myeloid Leukemia. Cell Stem Cell (2019) S1934-5909(19)30120-1. PMID: 31031138
  • Phase 1b study of venetoclax-obinutuzumab in previously untreated and relapsed/refractory chronic lymphocytic leukemia. Blood (2019) 133(2) 2765-2775. PMID: 30862645
  • Perineural invasion in pancreatic cancer: proteomic analysis and in vitro modelling. Mol Oncol (2019) 13(2) 1075-1091. PMID: 30690892
  • AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. J Clin Oncol (2019) 37(14):1188-1199. PMID: 30897038

Latest News

Areas of focus

Acute myeloid leukaemia
DLBCL - CD20 IHC

Kranc | Rouault-Pierre | Gallipoli | Cutillas

Lymphoma
FL cropped
Acute lymphoblastic leukaemia
DLBCL immunofluorescence - PMCH FITC
Chronic lymphocytic leukaemia
Follicular lymphoma - H&E
Stem Cell Biology
Hodgkins - EBV in situ hydribisation - blue
Immunotherapy
Vessels (CD31) CLL/SLL